文献速递甲状腺疾病

源自甲状腺乳头状癌患者的类器官培养

Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究建立了甲状腺乳头状癌(PTC)患者来源的类器官三维培养体系,可长期扩增。PTC类器官保留了原发肿瘤的组织病理学特征和基因组异质性,药物敏感性试验显示患者特异性药物反应且与突变谱高度相关。雌二醇在雌激素受体α(ERα)存在时促进PTC类器官细胞增殖,与ERβ和G蛋白偶联雌激素受体的表达无关。

要点

  • 患者来源PTC类器官可长期扩增并保留原发肿瘤组织病理学与基因组异质性。
  • PTC类器官药物敏感性呈现患者特异性,且与各自突变谱高度相关。
  • 雌二醇在ERα存在时促进PTC类器官增殖,与ERβ和GPER表达无关。

核心结论

  • PTC来源类器官可作为个性化抗癌药物临床反应研究的临床前模型。
  • ERα特异性拮抗剂可能为甲状腺癌预防和治疗提供潜在策略。

研究设计与样本

  • 手术切除的PTC原发组织经解离后用于类器官衍生。
  • 类器官进行组织学表征、DNA测序、药物筛选和细胞增殖试验。

主要发现

  • 建立了可长期扩增的患者来源PTC类器官三维培养体系。
  • PTC类器官保留原发肿瘤的组织病理学特征和基因组异质性。
  • 药物敏感性试验显示患者特异性药物反应,与各自突变谱高度相关。
  • 雌二醇在ERα存在时促进PTC类器官细胞增殖,与ERβ和GPER表达无关。

临床怎么用

  • 可将PTC类器官用于个性化抗癌药物反应评估。
  • ERα特异性拮抗剂可能作为甲状腺癌预防或治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Papillary thyroid cancer (PTC) has been one of the most frequent endocrine malignancies around the world. Although most PTC patients have a favorable prognosis, a subgroup of patients die, especially when disease recurrence occurs. There is a pressing need for clinically relevant preclinical thyroid cancer models for personalized therapy because of the lack of in vitro models that faithfully represent the biology of the parental tumors. OBJECTIVE: To understand thyroid cancer and translate this knowledge to clinical applications, patient-derived PTC organoids as a promising new preclinical model were established. METHODS: Surgically resected PTC primary tissues were dissociated and processed for organoid derivation. Tumor organoids were subsequently subjected to histological characterization, DNA sequencing, drug screen, and cell proliferation assay, respectively. RESULTS: We describe a 3-dimensional culture system for the long-term expansion of patient-derived PTC organoid lines. Notably, PTC organoids preserve the histopathological profiles and genomic heterogeneity of the originating tumors. Drug sensitivity assays of PTC organoids demonstrate patient-specific drug responses, and large correlations with the respective mutational profiles. Estradiol was shown to promote cell proliferation of PTC organoids in the presence of estrogen receptor α (ERα), regardless of the expression of ERβ and G protein-coupled ER. CONCLUSION: These data suggest that these newly developed PTC-derived organoids may be an excellent preclinical model for studying clinical response to anticancer drugs in a personalized way, as well as provide a potential strategy to develop prevention and treatment options for thyroid cancer with ERα-specific antagonists.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chen D, Tan Y, Li Z, et al. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2021. PMID: 33524147. doi:10.1210/clinem/dgab020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。